BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a R&D Day on Monday, October 2, at 9:00 a.m. EDT, virtually and in person in New York City.
During the event, Praxis' management team will review progress from its pipeline programs, including the anticipated initiation of the Phase 3 program for ulixacaltamide in essential tremor and advances in its clinical epilepsy assets.
Praxis' management team will be joined by key opinion leaders in Movement ...